Drugmakers Who Verify Challenged Orange Book Listings Are Likely to Face Antitrust and Civil Racketeering Claims, Lawyers Predict

Published on Dec 14, 2023

Drugmakers with allegedly improper patent listings in the Orange Book, the Food and Drug Administration’s publication of approved drug products, could face—among other repercussions—class action lawsuits for violations of antitrust and racketeering laws, experts told The Capitol Forum. In a September 2023 policy statement on the matter, the Federal Trade Commission said drugmakers should review […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2024 The Capitol Forum. All Rights Reserved.